PCA3

PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance

Francesco Cantiello, Giorgio Ivan Russo, Antonio Cicione, Matteo Ferro, Sebastiano Cimino, Vincenzo Favilla, Sisto Perdonà, Ottavio De Cobelli, Carlo Magno, Giuseppe Morgia, Rocco Damiano

Citations: 50 • 2015

PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols

Michael A. Liss, Rosanne Santos, Kathryn Osann, Alice Lau, Thomas E. Ahlering, David K. Ornstein

Citations: 31 • 2010

Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: potential implications for PSMA-PET patient selection

Matteo Droghetti, Lorenzo Bianchi, Massimiliano Presutti, Luigia Vetrone, Andrea Farolfi, Riccardo Mei, Francesca Giunchi, Alessio Degiovanni, Angelo Mottaran, Pietro Piazza, Danilo Cangemi, Paolo Castellucci, Antonietta D’Errico, Riccardo Schiavina, Eugenio Brunocilla, Stefano Fanti

Citations: 6 • 2024

Two-stage classifiers that minimize PCA3 and the PSA proteolytic activity testing in the prediction of prostate cancer recurrence after radical prostatectomy.

Daniel R. Jeske, Jenifer A Linehan, Timothy G. Wilson, Mark H. Kawachi, Kristina Wittig, Katarzya Lamparska, Camille Amparo, Rosa Mejia, Fang Lai, D.G. Georganopoulou, Steven S. Smith

Citations: 6 • 2017

Prostate‐specific membrane antigen ( <scp>PSMA)</scp> ‐ <scp>PET</scp> ‐avid prostate cancers show stronger <scp>PSMA</scp> immunohistochemistry staining on biopsy cores

Jonathon Carll, Henry Yen-Cheng Pan, Nathan Lawrentschuk, Andrew Ryan

Citations: 2 • 2026